Cancer-Focused Biotech Xilio Joins Packed IPO Pipeline
Cancer-focused biotechnology firm Xilio Therapeutics Inc. launched plans on Monday to conduct an estimated $125 million initial public offering, joining a packed pipeline of up to 13 operating companies planning to...To view the full article, register now.
Already a subscriber? Click here to view full article